The present study examined the efficacy of a pharmacological approach to suppress craniosynostosis through the inhibition of C-ROS-1 activity with crizotinib in Twist‐1del/+ mutant mice as a potential novel target for the treatment of SCS. This evidence concerns the gene ROS1 and craniosynostosis.